Uitgebreide gids binnenkort beschikbaar
We werken aan een uitgebreide educatieve gids voor de IV Iron Dose (Ganzoni Formula). Kom binnenkort terug voor stapsgewijze uitleg, formules, praktijkvoorbeelden en deskundige tips.
Intravenous (IV) iron replacement is indicated when oral iron is insufficient, intolerable, or contra-indicated — commonly in iron deficiency anaemia (IDA) associated with chronic kidney disease (CKD), inflammatory bowel disease, post-bariatric surgery malabsorption, heart failure, or pre-operative optimisation. The total iron deficit is calculated using the Ganzoni formula, developed by Alessandro Ganzoni in 1970, which accounts for the iron needed to correct the haemoglobin deficit plus a fixed amount to replenish storage iron. The formula is: Total Iron Deficit (mg) = Body Weight (kg) × (Target Hb − Current Hb)(g/dL) × 2.4 + Iron Stores. The factor 2.4 is derived from the fact that each gram of haemoglobin requires approximately 3.4 mg of iron, distributed through a blood volume of approximately 70 mL/kg, giving 3.4 × 70/100 ≈ 2.4 mg/kg per g/dL Hb deficit. The standard value for iron stores is 500 mg in adults weighing over 35 kg (250 mg if <35 kg or in children). A simplified modern formula widely used clinically is: Iron Deficit (mg) = Weight × (Target Hb − Current Hb) × 2.4 + 500. Common IV iron formulations include ferric carboxymaltose (Ferinject), iron sucrose (Venofer), low-molecular-weight iron dextran (CosmoFer/INFeD), and ferric derisomaltose (Monofer/Injectafer). The formulation determines the maximum single infusion dose, administration speed, and need for test dosing. Ferric carboxymaltose allows up to 1,000 mg per infusion and ferric derisomaltose up to 20 mg/kg (maximum 1,000 mg), making them the most practical for single-session repletion.
Ganzoni Formula: Iron Deficit (mg) = Weight (kg) × (Target Hb − Current Hb)(g/dL) × 2.4 + Iron Stores (mg) Iron Stores: 500 mg if weight ≥35 kg; 15 mg/kg if weight <35 kg Simplified Modern Formula: Iron Deficit (mg) = Weight (kg) × (Target Hb − Current Hb) × 2.4 + 500
- 1Confirm iron deficiency with serum ferritin (<30 mcg/L in uncomplicated IDA; <100 mcg/L with TSAT <20% in CKD or inflammatory states) and assess transferrin saturation (TSAT).
- 2Record current haemoglobin (g/dL) and body weight (kg). Set target Hb — typically 13 g/dL for men, 12 g/dL for women.
- 3Apply the Ganzoni or simplified formula to calculate total iron deficit in milligrams.
- 4Select IV iron formulation based on local availability, maximum infusion dose, and patient's renal and hepatic function.
- 5Divide total iron deficit by the maximum dose per infusion to determine the number of infusion sessions required.
- 6Administer IV iron per product-specific guidelines; monitor for infusion reactions (flushing, hypotension, anaphylaxis) during and 30 minutes post-infusion.
- 7Reassess ferritin, TSAT, and haemoglobin at 4–8 weeks post-repletion; repeat iron stores assessment at 3–6 months.
1–2 infusions of ferric carboxymaltose (max 1,000 mg/session); check Hb/ferritin at 4–6 weeks
Total iron deficit of 1,076 mg. With ferric carboxymaltose (max 1,000 mg per session), one infusion of 1,000 mg covers the bulk of the deficit. A follow-up session of 76 mg can be rounded up to 100 mg or reassessed after checking ferritin at 4 weeks.
CKD: treat when ferritin <500 mcg/L + TSAT <30%; one infusion session adequate
In CKD, iron deficiency thresholds are higher because inflammation elevates ferritin even in functionally iron-deficient patients. Ferritin <500 mcg/L with TSAT <30% warrants IV iron. One infusion of 860 mg (rounding to a standard formulation dose) achieves full repletion.
Single infusion 980 mg; IV iron + EPO if insufficient time; recheck Hb 2 weeks pre-op
Pre-operative anaemia significantly increases surgical risk and transfusion requirements. IV iron 4+ weeks before surgery allows adequate time for haemoglobin synthesis. If surgery is within 2 weeks, IV iron alone may be insufficient and erythropoiesis-stimulating agents may be added.
Iron stores = 15 mg/kg for children <35 kg; check paediatric IV iron dosing guidelines
In children and patients under 35 kg, iron stores are calculated at 15 mg/kg rather than the fixed 500 mg used in adults. Paediatric IV iron protocols specify reduced infusion rates and may require dilution; specialist paediatric or haematology guidance should be followed.
Professionals in finance and lending use Iron Deficit Iv as part of their standard analytical workflow to verify calculations, reduce arithmetic errors, and produce consistent results that can be documented, audited, and shared with colleagues, clients, or regulatory bodies for compliance purposes.
University professors and instructors incorporate Iron Deficit Iv into course materials, homework assignments, and exam preparation resources, allowing students to check manual calculations, build intuition about input-output relationships, and focus on conceptual understanding rather than arithmetic.
Consultants and advisors use Iron Deficit Iv to quickly model different scenarios during client meetings, enabling real-time exploration of what-if questions that would otherwise require returning to the office for detailed spreadsheet-based analysis and reporting.
Individual users rely on Iron Deficit Iv for personal planning decisions — comparing options, verifying quotes received from service providers, checking third-party calculations, and building confidence that the numbers behind an important decision have been computed correctly and consistently.
Extreme input values
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in iron deficit iv calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Assumption violations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in iron deficit iv calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Rounding and precision effects
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in iron deficit iv calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
| Formulation | Max Single Dose | Administration Rate | Test Dose Required |
|---|---|---|---|
| Ferric carboxymaltose (Ferinject) | 1,000 mg | 15 min IV infusion | No |
| Ferric derisomaltose (Monofer) | 20 mg/kg (max 1,000 mg) | 15–60 min | No |
| Iron sucrose (Venofer) | 200 mg | 30 min IV infusion | No |
| Ferric gluconate (Ferrlecit) | 125 mg per session | 60 min IV infusion | No |
| LMW iron dextran (CosmoFer) | Total dose infusion | 4–6 hours | No (observe closely) |
When is IV iron preferred over oral iron?
IV iron is preferred when oral iron is ineffective (malabsorption — coeliac disease, post-bariatric surgery, IBD), intolerable (GI side effects), insufficient for the deficit magnitude or urgency (pre-operative window, CKD on dialysis), or when compliance with oral therapy is poor. IV iron replenishes stores faster and more completely than oral iron in most settings.
What is the target haemoglobin in the Ganzoni formula?
Iron Deficit Iv is a specialized calculation tool designed to help users compute and analyze key metrics in the finance and lending domain. It takes specific numeric inputs — typically drawn from real-world data such as measurements, rates, or quantities — and applies a validated mathematical formula to produce actionable results. The tool is valuable because it eliminates manual calculation errors, provides instant feedback when exploring different scenarios, and serves as both a decision-support instrument for professionals and a learning aid for students studying the underlying principles.
What are the main IV iron formulations available?
Ferric carboxymaltose (Ferinject): max 1,000 mg/15 min infusion. Ferric derisomaltose (Monofer): max 20 mg/kg (up to 1,000 mg). Iron sucrose (Venofer): max 200 mg per infusion, given more slowly. Low-molecular-weight iron dextran (CosmoFer): total dose infusion possible but anaphylaxis risk requires test dose. High-dose formulations (carboxymaltose, derisomaltose) are preferred for efficiency.
How quickly does haemoglobin rise after IV iron?
Haemoglobin begins to rise within 1–2 weeks of IV iron, as the bone marrow has immediate access to iron for haemoglobin synthesis. Maximum Hb response is typically seen at 4–8 weeks. Ferritin and transferrin saturation normalise over the same period. If Hb fails to rise adequately by 4 weeks, alternative diagnoses (occult bleeding, vitamin B12/folate deficiency, haemolysis) should be investigated.
What is functional iron deficiency?
Functional iron deficiency occurs when there is sufficient total body iron but it is unavailable for erythropoiesis — typically because hepcidin, an acute-phase protein, blocks iron release from stores. It is common in CKD, heart failure, chronic inflammation, and on ESA therapy. Serum ferritin may be normal or elevated, but TSAT is low (<20%). IV iron bypasses the hepcidin block to some extent.
Is a test dose still required for modern IV iron formulations?
Test doses are no longer recommended for high-molecular-weight formulations that have been withdrawn (e.g., high-MW dextran). Modern formulations — ferric carboxymaltose, iron sucrose, and ferric derisomaltose — do not require routine test dosing but should be given in settings with resuscitation facilities. The first 15 minutes of infusion requires close observation for anaphylactoid reactions.
Can IV iron worsen infection?
In the context of Iron Deficit Iv, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and lending practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What is the difference between iron deficiency anaemia (IDA) and anaemia of chronic disease (ACD)?
IDA is caused by inadequate iron supply for erythropoiesis; ferritin is low, TSAT is low, and MCV is typically low. ACD is caused by inflammatory cytokines suppressing erythropoiesis and increasing hepcidin, trapping iron in stores; ferritin may be normal or elevated, TSAT is low, and MCV is usually normal. Distinguishing the two is critical because treating ACD with iron alone is ineffective without addressing the underlying inflammation.
Pro Tip
In patients with inflammatory conditions (CKD, IBD, cancer), serum ferritin is an acute-phase reactant and may be falsely elevated despite true iron deficiency. Use transferrin saturation (TSAT) as a more reliable indicator of functional iron availability — TSAT <20% alongside ferritin <100 mcg/L (or <300 mcg/L in CKD) supports iron deficiency even when ferritin appears adequate.
Wist je dat?
The human body contains approximately 3–5 grams of iron in total — enough to make a small nail. Of this, about 70% is in haemoglobin, 10% in myoglobin, and the rest in storage proteins ferritin and haemosiderin. The body loses only 1–2 mg of iron per day through skin shedding and GI losses, but menstruating women lose an additional 15–25 mg per menstrual cycle, explaining the high prevalence of iron deficiency in this group.
Referenties
- ›Ganzoni AM. Intravenous iron dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr. 1970;100(7):301-303.
- ›Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843.
- ›Muñoz M et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period. Transfus Med. 2018;28(1):22-39.
- ›NICE. Iron deficiency anaemia: management (QS114). 2016.
- ›Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200.